CIDMUS 50MG

CIDMUS 50MG TAB 14S is a prescribed medication consisting of two active ingredients: Sacubitril at a dose of 24 mg and Valsartan at a dose of 26 mg. This formulation falls under the category of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) and is primarily indicated for the management of chronic heart failure with reduced ejection fraction (HFrEF) in adults, as well as in certain pediatric cases for children aged 1 year and older. The total combined strength of the active components is denoted by “50MG,” while “14S” indicates the package contains 14 individual tablets. Chronic heart failure represents a progressive disorder characterized by the heart’s inability to pump sufficient blood to meet the physiological needs of the body, resulting in symptoms including shortness of breath, exhaustion, and edema. CIDMUS 50MG aims to enhance the heart’s pumping capacity, mitigate symptoms associated with heart failure, and significantly improve the overall health outcomes of affected patients. The specified dosage of 50MG serves as an initial or lower maintenance dosage, with the potential for healthcare providers to evaluate the patient’s response and make adjustments if necessary, including increasing to higher strengths such as CIDMUS 100mg or 200mg, depending on tolerability and clinical judgment. The mechanism of CIDMUS 50MG can be understood through the action of its components, where Valsartan acts as an Angiotensin Receptor Blocker, counteracting the effects of angiotensin II to lower blood pressure and reduce heart strain. Concurrently, Sacubitril functions as a neprilysin inhibitor, increasing levels of beneficial peptides that aid in blood vessel dilation and promote diuresis, resulting in additional cardiac support. Together, these actions contribute to decreased cardiac workload, improved circulatory function, and a reduction in heart failure symptoms, ultimately enhancing quality of life and reducing hospitalizations.